Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086970 | 0.81 | KMT2A (0.39) | CYP1B1CA12CA1CA9KMT2A | |
| SCHEMBL13250823 | 0.76 | TP53 (0.46) | KMT2APOLBALDH1A1MEN1MAPT | |
| SCHEMBL13250824 | 0.74 | TP53 (0.45) | KMT2AMAPTHPGD | |
| SCHEMBL6153208 | 0.73 | RGS4 (0.47) | CA12CA1CA9KMT2APOLB | |
| SCHEMBL10922984 | 0.72 | KMT2A (0.60) | CA12CA1CA9KMT2APOLB | |
| SCHEMBL20437111 | 0.72 | KMT2A (0.51) | CA12CA1CA9KMT2APOLB | |
| SCHEMBL29819860 | 0.72 | KMT2A (0.60) | CA12CA1CA9KMT2APOLB | |
| SCHEMBL2457896 | 0.72 | GSK3B (0.47) | CA12CA9POLBALDH1A1MAPT | |
| SCHEMBL12431374 | 0.71 | NPSR1 (0.53) | CYP1B1CA12CA1CA9KMT2A | |
| SCHEMBL2457775 | 0.71 | NPSR1 (0.56) | CYP1B1KMT2APOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399514-B1 | FLUORESCENT DIKETOPYRROLOPYRROLES | BASF SE (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7063806-B2 | Fluorescent diketopyrrolopyrroles | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040180235-A1 | Fluorescent diketopyrrolopyrroles | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-16 | — | — | US | disclosed |
| EP-1399514-A2 | FLUORESCENT DIKETOPYRROLOPYRROLES | Ciba SC Holding AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002672-A2 | FLUORESCENT DIKETOPYRROLOPYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180235-A1 | Fluorescent diketopyrrolopyrroles | TYR, QDPR, PDK1 | CYP1B1 530/4885CA12 4550/4885CA1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.